BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 12, 2004
 |  BioCentury  |  Strategy

Hoping one deal begets even more

Though Pliva d.d. may not seem the obvious choice for marketing a branded specialty product in the U.S., Indevus Pharmaceuticals Inc. thinks the Eastern European generics manufacturer is the perfect partner for its Sanctura trospium to treat overactive bladder (OAB). Under last week's deal, IDEV gets an experienced partner for which Sanctura will be its most important U.S. product, plus a funded sales force and plenty of cash to advance its pipeline and acquire additional products.

High on the list for IDEV was the partner's experience. Pliva (LSE:PLVD Zagreb, Croatia) has marketed trospium in Scandinavia and, through its U.S. subsidiary Odyssey Pharmaceuticals Inc., PLVD has experience in the U.S. urology market. Odyssey (East Hanover, N.J.) has marketed Urecholine bethanechol for urinary retention since acquiring the compound in 2000 from Merck & Co. Inc. (MRK, Whitehouse Station, N.J.).

Furthermore, PLVD will make Sanctura its most important product in the U.S. - a commitment IDEV said no other pharma company was willing to make. But perhaps most...

Read the full 821 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >